Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells
Brent N. Rexer(Breast Cancer Research Foundation), Carlos L. Arteaga(The University of Texas Southwestern Medical Center)
Cited by 77
Related Papers
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer
|Breast Cancer Research|2011|463
Association with HSP90 Inhibits Cbl-Mediated Down-regulation of Mutant Epidermal Growth Factor Receptors
|Cancer Research|2006|79
Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer
|Cancer Immunology Research|2022|59
Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer
|Nature Communications|2020|52
Proapoptotic Activity of Cell-Permeable Anti-Akt Single-Chain Antibodies
|Cancer Research|2005|50